The most clinically relevant adverse events associated with the use of 4-1BB agonist antibodies involve defects in immune homeostasis (e.g., neutropenia, thrombocytopenia, and reduced B cell numbers) (171, 172), as well as moderate to severe liver inflammation characterized by immune infiltration and concomitant elevation in serum levels of liver transaminases (e.g., AST, ALT). This evidence concerns the gene GPT and Thrombocytopenia.